Related Experiment Video
Updated: Apr 25, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Is resistance to dolutegravir possible when this drug is used in first-line therapy?
Thibault Mesplède1, Mark A Wainberg2
1McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755, Ch. Côte-Ste-Catherine, Montréal, QC, H3T1E2, Canada. tibo_mes@hotmail.com.
Abstract:
Dolutegravir (DTG) is an HIV integrase inhibitor that was recently approved for therapy by the Food and Drug Administration in the United States. When used as part of first-line therapy, DTG is the only HIV drug that has not selected for resistance mutations in the clinic. We believe that this is due to the long binding time of DTG to the integrase enzyme as well as greatly diminished replication capacity on the part of viruses that might become resistant to DTG. We further speculate that DTG might be able to be used in strategies aimed at HIV eradication.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Retroviruses
Inhibitors of Viral Protein Synthesis
Subviral Agents
Treatment Resistant Cancers

